AUID · authID Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on AUID. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About AUID · authID Inc.
authID Inc. provides biometric identity platform worldwide. The company offers cloud-based platform, including Biometric Identity Verification Proof, which establishes the identity of a user based on a variety of ground truth sources, including government-issued identity documents, such as national IDs, driver's licenses, passports, and electronic machine-readable travel documents; Verified platform, which detects presentation attack and spoofing threats; authID's Proof for identity verification product eliminates the need for costly and less accurate face-to-face, in-person ID checks; Biometric Identity Authentication Verified, which provides organization with a secure convenient solution to validate that individual is the verified account owner for various purposes, including passwordless login and performing specific transactions, and functions; PrivacyKey Privacy Preserving Biometrics solution provides biometric authentication without the requirement to store any biometri and derivative of biometric data; Account Access and Recovery, which allows users to recover, via a facial biometric, account access that is lost or blocked due to expired credentials, lockouts, lost or stolen devices, and compromised accounts. The company was formerly known as Ipsidy Inc. and changed its name to authID Inc. authID Inc. was founded in 2009 and is headquartered in Denver, Colorado.
Live Quote
SELL (score -9) · 12-1 mom -76.8% · RSI 38.7 · below_both · -81.8% from high
Targets blend Wall Street consensus (? analysts: low — / mean — / high —) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
authID is a pre-revenue-stage biometric identity verification company trading at $1.28 (micro-cap, ~$20M market cap) that has suffered a 75% drawdown from its 52-week high of $6.14. The investigation trigger cited 3 Form 4 filings in the last 14 days — but all three (CEO/CFO/CTO, filed 05/29, covering transactions dated 05/27) were stock OPTION GRANTS (transaction code A), not open-market purchases (code P). No actual equity was purchased in those transactions. The CEO's footnote stated options were granted to bring his stake to ~6% of outstanding shares, but that is a compensation/incentive alignment mechanism — not a market signal of undervaluation. The company's financials are deeply distressed: $480K quarterly revenue against $5M quarterly operating burn; accumulated deficit of $196M; going-concern opinion in the most recent 10-Q; only $1.2M cash vs. ~$3.8M senior secured debentures due October 2026 (just closed a bridge loan). No analyst coverage, illiquid micro-cap float (~14M shares), heavy warrant/option dilution overhang, and an active BIPA class-action lawsuit. The Rubidex partnership announced May 28 is the most concrete near-term catalyst but is insufficient to offset fundamental distress at this stage.